<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Economics</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Economics</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Экономика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-2329</issn><issn publication-format="electronic">2408-8986</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">35278</article-id><article-id pub-id-type="doi">10.22363/2313-2329-2023-31-2-238-252</article-id><article-id pub-id-type="edn">BMWFZA</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>INDUSTRIAL ORGANIZATION MARKETS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКОНОМИКА ОТРАСЛЕВЫХ РЫНКОВ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of the competitiveness of the biological pharmaceutical industry on the example of the United States</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ конкурентоспособности биологической фармацевтической промышленности на примере Cоединенных Штатов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Wang</surname><given-names>Kexin</given-names></name><name xml:lang="ru"><surname>Ван</surname><given-names>Кэсинь</given-names></name></name-alternatives><bio xml:lang="en">Graduate student of the Department of National Economics, Faculty of economics</bio><bio xml:lang="ru">аспирант кафедры национальной экономики экономического факультета</bio><email>1042218199@pfur.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1437-0008</contrib-id><name-alternatives><name xml:lang="en"><surname>Solovieva</surname><given-names>Yuliana V.</given-names></name><name xml:lang="ru"><surname>Соловьёва</surname><given-names>Юлиана Владимировна</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат экономических наук, доцент, доцент кафедры национальной экономики экономического факультета</p></bio><email>solovyeva-yuv@rudn.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">RUDN University</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-06-30" publication-format="electronic"><day>30</day><month>06</month><year>2023</year></pub-date><volume>31</volume><issue>2</issue><issue-title xml:lang="en">CHALLENGES FOR SUSTAINABLE DEVELOPMENT:  GLOBAL PARTNERSHIP IN A NEW ENVIRONMENT</issue-title><issue-title xml:lang="ru">ПРОБЛЕМЫ УСТОЙЧИВОГО РАЗВИТИЯ:  ГЛОБАЛЬНОЕ ПАРТНЕРСТВО В НОВЫХ УСЛОВИЯХ</issue-title><fpage>238</fpage><lpage>252</lpage><history><date date-type="received" iso-8601-date="2023-07-07"><day>07</day><month>07</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Wang K., Solovieva Y.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Ван К., Соловьёва Ю.В.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Wang K., Solovieva Y.V.</copyright-holder><copyright-holder xml:lang="ru">Ван К., Соловьёва Ю.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/economics/article/view/35278">https://journals.rudn.ru/economics/article/view/35278</self-uri><abstract xml:lang="en"><p style="text-align: justify;">Since entering the era of bioeconomy, the biotechnology industry economy represented by the bio pharmaceutical industry is leading a new wave of technological revolution. China’s strategic deployment for the bio pharmaceutical industry economy has achieved remarkable results, but there is still a large competitive gap compared with the United States and other biomedical powers. The goal of this article is to study the American biomedical market and find out the gap, so as to provide inspiration for the development of the biomedical industry in China and other countries. The Porter Diamond Model is used to build the theoretical research method analysis framework of the international competitiveness of the bio pharmaceutical industry. Taking the United States as an example, the paper analyzes its competitive advantages in six aspects: the elements of the biomedical industry, the enterprise structure and competition, the demand conditions, the relevant and supporting industries, the government and development opportunities. Based on this, the paper puts forward policy recommendations conclusions for China’s development of the bio pharmaceutical industry, so as to provide reference value for the development of the pharmaceutical industry.</p></abstract><trans-abstract xml:lang="ru"><p style="text-align: justify;">С момента вступления в эпоху биоэкономики экономика биотехнологической отрасли, представляемая биофармацевтической промышленностью, влечет за собой новую волну технологической революции. Стратегическое развертывание Китая в сфере экономики фармацевтической промышленности достигло значительных результатов, однако по-прежнему наблюдается большой конкурентный разрыв по сравнению с США и другими биомедицинскими державами. Цель исследования - изучить американский биомедицинский рынок и выяснить существующий разрыв, оказывающий влияние на развитие биомедицинской индустрии в Китае и других странах. Для проведения анализа методов исследования международной конкурентоспособности фармацевтической промышленности в работе используется Алмазная модель Портера. Базируясь на примере США, анализируются конкурентные преимущества в шести аспектах: элементы биомедицинской промышленности, структура предприятия и конкуренция, условия спроса, соответствующие и поддерживающие отрасли, правительство и возможности развития. Исходя из этого, даются рекомендации, направленные на формирование политики, способствующей развитию биологической фармацевтической промышленности Китая.</p></trans-abstract><kwd-group xml:lang="en"><kwd>bio pharmaceutical industry economy</kwd><kwd>biomedicine</kwd><kwd>China</kwd><kwd>USA</kwd><kwd>international competitiveness</kwd><kwd>Porter Diamond Model</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>экономика биофармацевтической промышленности</kwd><kwd>биомедицина</kwd><kwd>Китай</kwd><kwd>США</kwd><kwd>международная конкурентоспособность</kwd><kwd>Алмазная модель Портера</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Carlson, R. (2016). Estimating the biotech sector’s contribution to the US economy. Nature Biotechnology, 34(3), 247-255. https://doi.org/10.1038/nbt.3491</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Chung, T.W. (2016). A study on logistics cluster competitiveness among Asia main countries using the Porter’s Diamond Model. The Asian Journal of Shipping and Logistics, 32(4), 257-264. https://doi.org/10.1016/j.ajsl.2016.12.010</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Fang, K., Zhou, Y.H, &amp; Wang, S. (2018). Assessing national renewable energy competitiveness of the G20: A revised Porter’s Diamond Model. Renewable and Sustainable Energy Reviews, 93(1), 719-731. https://doi.org/10.1016/j.rser.2018.05.011</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Graul, A.I., Pina, P., &amp; Cruces, E. (2019). 2018 Global New Drug R&amp;D Report Part 1: New Drugs and Biological Agents. Pharmaceutical Progress, 41(4), 309-317. https://doi.org/10.1358/dot.2019.55.1.2959663</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Guo, Z.P. (2020). Current situation and development of research on biological drugs and biological analogues. Journal of Clinical Pharmacotherapy, 18(5), 1-6.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hernández, H., Grassano, N., &amp; Tübke A. (2019). The 2019 EU industrial R&amp;D investment scoreboard. (p. 62). Luxembourg: Publications Office of the European Union. https://doi.org/10.2760/04570</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hodgson, J. (2020). The pandemic pipeline. Nature Biotechnology, 38(5), 523-532. https://doi.org/10.1038/d41587-020-00005-z</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Huang, Wei (2006). Research on Venture Capital Model of Biomedical Industry [dissertation]. China, Shanghai: Fudan University.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ji, Lei, Li, H.Y, &amp; Wang, Y. (2019). Analysis on the competitiveness of Shandong marine bio pharmaceutical industry based on the diamond model. Fisheries Research, 41(5), 430-440. http://www.hyyysci.com/EN/Y2019/V41/I5/430</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Irfan, M., Zhao, Z.Y., &amp; Ahmad, M. (2019). Critical factors influencing wind power industry: A Diamond Model based study of India. Energy Reports, 5(1), 1222-1235. https://doi.org/10.1016/j.egyr.2019.08.068</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lindburg, L., Bozinovic, L., &amp; Susek, R. (2019). As the life science industry evolves, so do its talent needs. Nature Biotechnology, 37(4), 481-483. https://doi.org/10.1038/s41587-019-0091-5</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Morrison, C. (2020). 2019 Biotech IPOs: Party on. Nature Reviews Drug Discovery, 49(1), 6-9. https://doi.org/10.1038/d41573-019-00213-6</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ozer K.O., Latif, H., &amp; Sariisik, M. (2012). International competitive advantage of Turkish tourism industry: A comparative analysis of Turkey and Spain by using the Diamond Model of M. Porter. Procedia-Social and Behavioral Sciences, 58(1), 1064-1076. https://doi.org/10.1016/j.sbspro.2012.09.1087</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Porter, M. (2002). National Competitive Advantage. Beijing Hua Xia Publishing House. Pp. 123-136.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Qian, J.Y., &amp; Yu, Zheng (2020). Analysis on the international competitiveness of China’s biopharmaceutical industry. China Pharmaceutical Affair, 34(5), 549-555. https://doi.org/10.16153/j.1002-7777.2020.05.008</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Shi, G., &amp; Liu, F.Y. (2016). Current situation and countermeasures of China’s biomedical industry development. China Health Policy Research, 9(3), 16-19.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang, F. (2019). Upgrading Law and Enlightenment of Innovation in American Biomedical Industry. Nanjing Social Sciences, 30(8), 29-35.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zhao, B., Zhang, D.S., &amp; Zhao, Y.Z. (2011). Research on the competitiveness of regional biomedical industry based on the diamond model: take Shijiazhuang as an example. Chinese Journal of Bioengineering, 31(9), 140-145. https://manu60.magtech.com.cn/biotech/CN/Y2011/V31/I9/140</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zhang, Qing (2011). Development Characteristics and Enlightenment of American Biomedical Industrial Park. China Hi-tech Zone, 11(4), 111-113.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zhang, J.C. (2001). Research on Theory and Method of International Competitiveness Evaluation [dissertation]. China, Beijing: Graduate School of Chinese Academy of Social Sciences.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zhang, J.R. (2015). Experience and Inspiration of the Development of American Biomedical Industry. Business Research, 39(12), 24-28.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Zheng, X.F. (2011). Innovation of American Biotechnology Industry Cluster and Its Inspiration to China. Journal of Hainan University (Humanities and Social Sciences Edition), 29(3), 50-54. https://doi.org/10.3969/j.issn.1004-1710.2011.03.009</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zhu, Xing, &amp; Xu, Fu (2015). Research on distribution and trend of biomedical patents. Chinese Journal of New Drugs, 24(15), 1686-1693. www.cqvip.com/qk/97417x/201515/665635479.html</mixed-citation></ref></ref-list></back></article>
